On July 26, 2021 Royalty Pharma Holdings Ltd. reported that (pricing of $600,000,000 aggregate principal amount of 2.150% Senior Notes due 2031 (the "2031 Notes") and $700,000,000 aggregate principal amount of 3.350% Senior Notes due 2051 (the "2051 Notes" and, together with the 2031 Notes, the "Notes") on July 26, 2021, the Issuer, (the "Guarantor") and Wilmington Trust, National Association, as trustee (the "Trustee"), entered into a second supplemental indenture (the "Second Supplemental Indenture") to the Indenture dated as of September 2, 2020 (the "Base Indenture" and together with the Second Supplemental Indenture, the "Indenture"), providing for the issuance of the Notes (Filing, 8-K, Royalty Pharma , JUL 26, 2021, View Source [SID1234585184]). The Notes will be guaranteed on a senior unsecured basis by the Guarantor.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2031 Notes will bear interest at a fixed rate of 2.150% per annum, and interest will be payable on March 2 and September 2 of each year, beginning March 2, 2022, until the maturity date of September 2, 2031. The 2051 Notes will bear interest at a fixed rate of 3.350% per annum, and interest will be payable on March 2 and September 2 of each year, beginning March 2, 2022, until the maturity date of September 2, 2051. The Issuer may redeem the Notes at such times and at the redemption prices as provided for in the Indenture. The Indenture also contains certain covenants as set forth in the Indenture and requires the Issuer to offer to repurchase the Notes upon certain change of control events.

The foregoing description of the Indenture and the Notes is qualified in its entirety by reference to the full text of the Base Indenture and the Second Supplemental Indenture (including the form of Notes) which are filed as Exhibits 4.1 and 4.2 to this Current Report on Form 8-K, respectively, and are incorporated herein by reference.